8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
04. Dezember 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11. November 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
04. November 2024 07:08 ET
|
Can-Fite BioPharma Ltd.
Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a...
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
18. Oktober 2024 09:06 ET
|
Can-Fite BioPharma Ltd.
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) --...
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
09. Oktober 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
07. Oktober 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
24. September 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
16. September 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
29. August 2024 08:15 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
08. August 2024 19:01 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...